Board of directors

Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics. 25 years of experience from leading positions in banking, life science and healthcare. CEO, Investor Growth Capital (renamed as Patricia Industries) during 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industrial and healthcare. Former board member in life science companies, e.g. Swedish Orphan International AB (chairman) and Carmel Pharma AB.

Other current engagement: Board member in Biotage AB, Bio-Works Technologies AB, Bio-Works Sweden AB, Boule Diagnostics AB, Excillum Aktiebolag, Immedica Pharma Holding AB, Mabtech Group Holding AB, Mabtech Holding AB, Surgical Science Sweden AB, Swedencare AB (publ) and board member in affiliates to these companies and smaller family companies.

Shareholding in Sedana Medical: Shareholding in Sedana Medical: 1,666,464 shares via Tedsalus AB. Independent in relation to the Company and its management and in relation to major shareholders.

Education and professional experience: Claus holds an M.Sc. from the Copenhagen Business School and an MBA in Strategy and Finance from the UCLA Anderson School of Management. He served as CEO of Atos Medical from early 2014 through 2018. Atos Medical was sold by EQT to PAI Partners during his tenure in 2016. From 2006 to 2014, Claus held numerous senior leadership positions with Coloplast A/S, a Danish global consumable Medtech company, most recently as President, North America, Japan, and Australia. Before joining Coloplast, Claus spent 10 years within corporate strategy, mergers and acquisitions, and private equity across industries working for McKinsey & Company, Nordic Capital, and Mattel.

Other current engagement: Claus is currently ordinary member of the board of directors and vice chairman of the board of Ellab, owned by EQT, and senior advisor at KKR & Co, Inc.

Shareholding in Sedana Medical: 0 shares. Independent of major shareholders, not independent of the Company and the Executive Management.

Education and professional experience: Bengt is a qualified pharmacist, M.Sc. from Uppsala University. Bengt has more than 30 years of experience in the life science industry. Owner and Chairman in Linc AB, with investments in the pharmaceutical and Medtech industry.

Other current engagement: Chairman in Linc AB and Knil AB. Board member in Animal Probiotics Sweden AB, Cronhamn Invest AB, Livland Skog AB, Medivir Aktiebolag, nWise AB, Part Production Sweden AB, Reison Medical AB, Stille AB and Swevet Holding AB. Board member and deputy board member in affiliates to these companies and smaller family companies.

Shareholding in Sedana Medical: 7,598,804 shares via Linc AB. Independent in relation to the Company and its management but not in relation to major shareholders.

Education and professional experience: Ola holds an upper secondary school qualification in engineering specializing in chemistry from Gothenburg Technical Upper Secondary School. Ola has more than 25 years of experience in the pharmaceutical industry mainly within marketing, sales, and different management positions including 4 years in the US for Pharmacia in the 80ies and 90ies. Ola also has more than 20 years of experience in the medical device industry as CEO for Louis Gibeck AB where he was responsible for the listing on the OTC exchange in Stockholm and as Managing Director EMEA, Hudson RCI AB after its acquisition of Louis Gibeck AB. Ola was the founder of Sedana Medical 2005 and acted as CEO up to 2011.

Other current engagement: Chairman in Eataway AB. Board member in TransCutan AB and board member in smaller family companies.

Shareholding in Sedana Medical: 4,629,728 shares privately and via Magiola Consulting AB. Independent in relation to the Company and its management and in relation to major shareholders.

Education and professional experience: Christoffer has a Master of Science degree from Chalmers University of Technology and a degree in economics from the School of Business and Economics at the University of Gothenburg. During 2012-2020 he was CFO for XVIVO Perfusion AB. During the years 2015–2017, he led XVIVO’s North American operations and resided in the United States. From 2001 to 2012, he has had leading positions in finance and strategic management at Novartis and LG Electronics.

Other current engagement: COO (since 2020) and Vice President (since 2017) at XVIVO Perfusion AB.

Shareholding in Sedana Medical: 0 shares. Independent in relation to the Company and its management and in relation to major shareholders.

Education and professional experience: Eva has a BSc from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and medical technology industry, mainly in marketing and sales as well as management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.

Other current engagement: Vice President Marketing Director at Olink Proteomics AB, board member at Senzime AB, CEO and Chairman of the board in the own company Movits Consulting AB and deputy board member in Finnson & Partners AB.

Shareholding in Sedana Medical: 12,800 shares. Independent in relation to the Company and its management and in relation to major shareholders.